Researchers conducted a large-scale pooled analysis for associations between patients achieving complete response or better with MRD-negative status and progression-free survival. People who were MRD negative with ≥CR have improved PFS, regardless of therapy, versus those who do not reach CR or are MRD positive.

Reference: Blood 2022 Feb 10; 139(6): 835–844.